Eyegate Pharmaceuticals, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Waltham MA United States (1998)
Status: No NME R&D (1998)

Organization Overview

First Clinical Trial
2008
NCT00698425
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

EyeGate

Active Ingredients

Drugs in Phase 3 Trials (3)

prednisone (meticorten) (2 trials)

sodium citrate (4 trials)

urea (8 trials)

Drugs in Phase 2 Trials (2)

Key: Eyegate Pharmaceuticals, Inc. (1) Acquired (1)

dexamethasone (2 trials)

pp-001 (2 trials)

Drugs in Phase 1 Trials (1)

citric acid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cataract (Phase 2)

Dry Eye Syndromes (Phase 3)

Edema (Phase 2)

Inflammation (Phase 2)

Iridocyclitis (Phase 3)

Keratoconjunctivitis Sicca (Phase 3)

Macular Edema (Phase 2)

Pain, Postoperative (Phase 2)

Uveitis (Phase 3)

Uveitis, Anterior (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 6